Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein

Acta Pharmacologica Sinica

Volumn 24, Issue 10, 2003, Pages 1027-1032+1062

  Ma, Feng Xia ^a   Liu, Li Ying ^a   Xiong, Xiao Ming ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Endothelium; Lipoproteins; Lovastatin; Malondialdehyde; Muscle relaxation; Nitric oxide; Rats; Superoxide dismutase

Indexed keywords

ACETYLCHOLINE; LIPID; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MEVINOLIN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; DESCENDING AORTA; DRUG MECHANISM; ENZYME ACTIVITY; HEART PROTECTION; LIPID BLOOD LEVEL; MALE; NONHUMAN; RAT; THORACIC AORTA; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA, THORACIC; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; LOVASTATIN; MALE; MALONDIALDEHYDE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 0141960888     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Scandinavian simvastatin survival study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-9.
2. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13.
3. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for presence of oxidatively modifed low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-95.
4. Plane F, Bruckdorfer KR, Kerr P, Steuer A, Jacobs M. Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated endothelial derived nitric oxide in rabbit aorta. Br J Pharmacol 1992; 105: 216-22.
5. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
6. Calara F, Dimayuga P, Niemann A, Thyberg T, Diczfalusy U, Witztum JL, et al. An animal mode to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 1998; 18: 884-93.
7. Niu XL, Liu LY, Chen X. Some similarities in vascular effects of oleic acid and oxidized low-density lipoproteins on rabbit aorta. J Mol Cell Cardiol 1995; 27: 531-9.
8. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, et al. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998; 31: 190-4.
9. Green LC, Wagner DA, Gligowski J. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal Biochem 1982; 126: 131-4.
10. Liu LY, Chen X, Wu CL. Protective effects of gensenosides against renal injuries induced by cisplatin in rats. Chin J Pharmacol Toxicol 1995; 1: 27-9.
11. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem 1984; 142: 290-6.
12. Jiang JL, Li NS, Li YJ, Deng HW. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002; 135: 1175-82.
13. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990; 9: 515-40.
14. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9.
15. Rosenson RS. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999; 1: 225-32.